JNJ-Q2 is a Phase III-ready investigational novel fluoroquinolone antibiotic that has been shown to be effective in a Phase II study of acute bacterial and skin and skin structure infections (ABSSSI).
Furiex acquired these rights as a result of Janssen’s decision not to exercise its option under the agreement that gave Janssen the opportunity to continue development of JNJ-Q2.
The company is currently conducting a Phase II study in patients with community acquired bacterial pneumonia (CABP).
Furiex chairman Fred Eshelman said the company plans to evaluate strategic partnering and financing options to fund the initiation and completion of Phase III clinical trials for JNJ-Q2.
"Furiex is planning an End of Phase II meeting with the FDA this year to begin the transition process to Phase III development for ABSSSI. We look forward to advancing the development of JNJ-Q2 and providing further details regarding this program as it progresses," Eshelman said.
Furiex may owe payments to Janssen based on future regulatory milestones and, if approved, sales milestones and royalties.